[HTML][HTML] Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis …
L Rivera, TF Schwarz, KH Kim, YK Kim, U Behre… - Vaccine, 2018 - Elsevier
Background This study evaluated the immunogenicity and safety of quadrivalent
meningococcal conjugate vaccine using tetanus (T) toxoid as carrier protein (MenACWY-TT) …
meningococcal conjugate vaccine using tetanus (T) toxoid as carrier protein (MenACWY-TT) …
Comparison of the safety and immunogenicity of a novel quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine and a marketed quadrivalent …
SA Halperin, Y Baine, JB Domachowske… - Journal of the …, 2014 - academic.oup.com
Background Universal immunization of adolescents against meningococcal disease with a
quadrivalent meningococcal ACWY (MenACWY) conjugate vaccine is recommended in a …
quadrivalent meningococcal ACWY (MenACWY) conjugate vaccine is recommended in a …
Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine …
R Gasparini, M Conversano, G Bona… - Clinical and Vaccine …, 2010 - Am Soc Microbiol
This study evaluated the safety, tolerability, and immunogenicity of an investigational
quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, when administered …
quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, when administered …
[HTML][HTML] Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine in healthy meningococcal-naive children 2–9 years of age: a phase III …
CI Baccarini, MW Simon, D Brandon… - The Pediatric …, 2020 - journals.lww.com
Background: Invasive meningococcal disease is a major cause of meningitis in children. An
investigational meningococcal (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine …
investigational meningococcal (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine …
Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to …
R Baxter, Y Baine, K Ensor, V Bianco… - The Pediatric …, 2011 - journals.lww.com
Background: An investigational quadrivalent Neisseria meningitidis serogroups A, C, W-135,
and Y tetanus toxoid conjugate vaccine (MenACWY-TT) has been developed to expand …
and Y tetanus toxoid conjugate vaccine (MenACWY-TT) has been developed to expand …
[HTML][HTML] Safety and immunogenicity of an investigational quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) co-administered with routine …
MJ Cornish, JA Hedrick, AA Gabrielsen, AD Johnson… - Vaccine, 2022 - Elsevier
Abstract Background The MenACYW-TT conjugate vaccine is approved for prevention of
invasive meningococcal disease (IMD) as a single dose in individuals≥ 2 years of age in …
invasive meningococcal disease (IMD) as a single dose in individuals≥ 2 years of age in …
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study
T Vesikari, R Borrow, A Forsten, H Findlow… - Human vaccines & …, 2020 - Taylor & Francis
Neisseria meningitidis can lead to invasive meningococcal disease to which young children
are particularly vulnerable. We assessed the immunogenicity and safety of Sanofi Pasteur's …
are particularly vulnerable. We assessed the immunogenicity and safety of Sanofi Pasteur's …
Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered in healthy meningococcal vaccine-naïve children (2-9 …
M Simon, A Zomcik, D Brandon, S Christensen… - 2021 - publications.aap.org
Background MenACYW-TT is an investigational quadrivalent meningococcal conjugate
vaccine that contains tetanus toxoid as carrier protein. The vaccine is intended for global use …
vaccine that contains tetanus toxoid as carrier protein. The vaccine is intended for global use …
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a …
MS Dhingra, L Namazova-Baranova… - Epidemiology & …, 2021 - cambridge.org
Invasive meningococcal disease has high morbidity and mortality, with infants and young
children among those at greatest risk. This phase III, open-label, randomised study in …
children among those at greatest risk. This phase III, open-label, randomised study in …
[HTML][HTML] A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the …
LJ Chang, J Hedrick, S Christensen, J Pan, E Jordanov… - Vaccine, 2020 - Elsevier
Background MenACYW-TT is an investigational quadrivalent meningococcal conjugate
vaccine intended for use in individuals≥ 6 weeks of age. We evaluated the safety and …
vaccine intended for use in individuals≥ 6 weeks of age. We evaluated the safety and …